PMID- 37964480
OWN - NLM
STAT- MEDLINE
DCOM- 20240125
LR  - 20240417
IS  - 1752-8062 (Electronic)
IS  - 1752-8054 (Print)
IS  - 1752-8054 (Linking)
VI  - 17
IP  - 1
DP  - 2024 Jan
TI  - Risk factors for hyperglycemia in COVID-19 patients treated with remdesivir.
PG  - e13684
LID - 10.1111/cts.13684 [doi]
LID - e13684
AB  - The primary objective of this study was to investigate the factors contributing 
      to hyperglycemic adverse events (AEs) associated with the administration of 
      remdesivir in hospitalized patients diagnosed with coronavirus disease 2019 
      (COVID-19). Furthermore, the study aimed to develop a risk score model employing 
      various machine learning approaches. A total of 1262 patients were enrolled in 
      this investigation. The relationship between covariates and hyperglycemic AEs was 
      assessed through logistic regression analysis. Diverse machine learning 
      algorithms were employed for the purpose of forecasting hyperglycemia-related 
      complications. After adjusting for covariates, individuals with a body mass index 
      >/=23 kg/m(2) , those using proton pump inhibitors, cholinergic medications, or 
      individuals with cardiovascular diseases exhibited approximately 2.41-, 2.73-, 
      2.65-, and 1.97-fold higher risks of experiencing hyperglycemic AEs (95% CI 
      1.271-4.577, 1.223-6.081, 1.168-5.989, and 1.119-3.472, respectively). 
      Multivariate logistic regression, elastic net, and random forest models displayed 
      area under the receiver operating characteristic curve values of 0.65, 0.66, and 
      0.60, respectively (95% CI 0.572-0.719, 0.640-0.671, and 0.583-0.611, 
      respectively). This study comprehensively explored factors associated with 
      hyperglycemic complications arising from remdesivir administration and, 
      concurrently, leveraged a range of machine learning methodologies to construct a 
      risk scoring model, thereby facilitating the tailoring of individualized 
      remdesivir treatment regimens for patients with COVID-19.
CI  - (c) 2023 The Authors. Clinical and Translational Science published by Wiley 
      Periodicals LLC on behalf of American Society for Clinical Pharmacology and 
      Therapeutics.
FAU - Kim, Woorim
AU  - Kim W
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
AD  - Department of Pharmacy, Kangwon National University, Chuncheon, Korea.
FAU - Lee, Go Woon
AU  - Lee GW
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
AD  - Department of Pharmacy, Bestian Hospital, Cheongju-si, Korea.
FAU - Rhee, Nuga
AU  - Rhee N
AD  - Medical Department, Bestian Hospital, Cheongju-si, Korea.
FAU - Min, Kyung Hyun
AU  - Min KH
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
FAU - Kim, Jun Hyeob
AU  - Kim JH
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
FAU - Gil, Jin Yeon
AU  - Gil JY
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
FAU - Kim, Song Yi
AU  - Kim SY
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
AD  - National Institute of Food and Drug Safety Evaluation, Cheongju-si, Korea.
FAU - Han, Ji Min
AU  - Han JM
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
FAU - Lee, Kyung Eun
AU  - Lee KE
AD  - College of Pharmacy, Chungbuk National University, Cheongju-si, Korea.
LA  - eng
GR  - 2021RIS-001/Regional Innovation Strategy/
GR  - 2017R1A5A2015541/Medical Research Center Program/
GR  - National Research Foundation funded by the Korean Government Ministry of 
      Education and Ministry of Science and Information and Communication Technology 
      (ICT)/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20231128
PL  - United States
TA  - Clin Transl Sci
JT  - Clinical and translational science
JID - 101474067
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Humans
MH  - *COVID-19
MH  - COVID-19 Drug Treatment
MH  - Risk Factors
MH  - *Hyperglycemia
MH  - Adenosine Monophosphate/*analogs & derivatives
MH  - Alanine/*analogs & derivatives
PMC - PMC10766056
COIS- All the authors have declared that they have no competing interests.
EDAT- 2023/11/15 06:42
MHDA- 2024/01/25 06:43
PMCR- 2023/11/28
CRDT- 2023/11/15 00:33
PHST- 2023/09/26 00:00 [revised]
PHST- 2023/06/29 00:00 [received]
PHST- 2023/10/28 00:00 [accepted]
PHST- 2024/01/25 06:43 [medline]
PHST- 2023/11/15 06:42 [pubmed]
PHST- 2023/11/15 00:33 [entrez]
PHST- 2023/11/28 00:00 [pmc-release]
AID - CTS13684 [pii]
AID - 10.1111/cts.13684 [doi]
PST - ppublish
SO  - Clin Transl Sci. 2024 Jan;17(1):e13684. doi: 10.1111/cts.13684. Epub 2023 Nov 28.